Kalkine: EVE Health Group (ASX:EVE) Strengthens Position in Regulated Healthcare with Nextract Acquisition

June 12, 2025 06:06 PM AEST | By Team Kalkine Media

Google News:

Kalkine: EVE Health Group (ASX:EVE) Strengthens Position in Regulated Healthcare with Nextract Acquisition — Image source: Shutterstock

Recent News

Kalkine : Brambles Ltd (ASX:BXB) Strengthens Position in Australia Sha...

Kalkine : Retail Stock AX1 Plunges Amid ASX 200 Volatility Triggered b...

King River Resources (ASX:KRR) Expands Tenement Holdings While Advanci...

Kalkine : ASX All Ordinaries Edges Higher Led by Gold and Energy Stoc...

Highlights

EVE completes strategic acquisition of Nextract Pty Ltd

New therapeutic products target major global health markets

Leadership reshuffle supports growth in regulated healthcare

EVE Health Group (ASX:EVE) has officially finalized the acquisition of Nextract Pty Ltd, marking a significant step in its evolution toward becoming a key player in the regulated healthcare space. The acquisition was completed through the issuance of 83,333,333 new ordinary shares at an issue price of $0.036 per share. To further support integration and compliance-related milestones, a $1 million placement was executed via the allotment of 27,777,778 shares under the same pricing terms.

Expanding into High-Growth Health Segments

This strategic acquisition brings into EVE Health’s fold a focused pipeline aimed at addressing substantial unmet medical needs. Nextract’s flagship innovation targets the erectile dysfunction segment, a global market estimated at US$5.3 billion, with a formulation offering a rapid onset of action—within just 15 minutes. Parallel development is underway on a second product addressing dysmenorrhea, a condition affecting millions globally and linked to a US$10.9 billion market. Notably, this second therapeutic solution is exploring an alternative manufacturing route aimed at enhancing its commercial scalability.

Capital Strategy and Funding

To complement the placement and ensure broader shareholder participation, EVE Health has launched a Share Purchase Plan (SPP) aiming to raise up to $500,000. This initiative allows eligible shareholders to subscribe for shares at the same price as the initial placement, strengthening the company’s funding base to support product integration and regulatory planning.

Leadership Transitions to Support Scientific Advancement

EVE Health has also announced important changes at the executive level. Dr. Stuart Gunzburg has taken on the dual role of Chief Scientific Officer and Executive Director, bringing scientific leadership aligned with the company’s expanding therapeutic focus. Meanwhile, Carlos Jin has retired from the Board, and Bill Fry has transitioned into a Non-Executive Director role, reinforcing governance while enabling fresh scientific leadership at the helm.

Strategic Vision Aligned with Innovation

Chairman Rodney Hannington emphasized the transformational nature of the acquisition. With Nextract now integrated, EVE Health is well-positioned to advance its proprietary delivery technologies, which are tailored to improve patient adherence and speed of therapeutic effect. The move underlines EVE Health’s commitment to innovation that addresses real-world clinical challenges.

With this milestone, EVE Health (EVE) signals a strong push toward expanding its capabilities in the regulated health space and advancing its pipeline of next-generation therapeutic solutions.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.